RXRX:NASDAQRecursion Pharmaceuticals, Inc. Analysis

Recursion Pharmaceuticals (RXRX) sits at a crossroads where technical signals and fundamentals clash. The stock trades near its 20‑day SMA (≈$3.44) and 50‑day SMA (≈$3.31) with a neutral trend, but the MACD is bearish (‑0.088 vs signal ‑0.002) and RSI sits at 40, hinting at modest downside pressure. Volatility is extreme (≈61% 30‑day) and beta is high (≈2.9), while the recent price dip to $3.42 reflects a sharp short‑term pullback. Fundamentally, the company is loss‑making with a 56% revenue decline, negative operating margins (‑19.9%), zero EPS and a sky‑high price‑to‑sales multiple (~24x), making the current valuation appear overvalued.
On the upside, the AI‑driven drug discovery platform is gaining visibility, highlighted by recent inclusion in the Russell 2000 Value Index and partnerships with Roche, Sanofi and Bayer. The “Extreme Greed” sentiment (Fear‑Greed Index 90.8) suggests speculative interest, but the combination of high drawdown (‑58%) and deteriorating cash flow underscores substantial downside risk.